JP2024542159A5 - - Google Patents

Info

Publication number
JP2024542159A5
JP2024542159A5 JP2024527078A JP2024527078A JP2024542159A5 JP 2024542159 A5 JP2024542159 A5 JP 2024542159A5 JP 2024527078 A JP2024527078 A JP 2024527078A JP 2024527078 A JP2024527078 A JP 2024527078A JP 2024542159 A5 JP2024542159 A5 JP 2024542159A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
determination region
containing seq
chain complementarity
complementarity determination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/048887 external-priority patent/WO2023081317A2/en
Publication of JP2024542159A publication Critical patent/JP2024542159A/ja
Publication of JP2024542159A5 publication Critical patent/JP2024542159A5/ja
Pending legal-status Critical Current

Links

JP2024527078A 2021-11-04 2022-11-03 Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置 Pending JP2024542159A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275890P 2021-11-04 2021-11-04
US63/275,890 2021-11-04
PCT/US2022/048887 WO2023081317A2 (en) 2021-11-04 2022-11-03 Treatment of cancer with nk cells and multispecific engagers

Publications (2)

Publication Number Publication Date
JP2024542159A JP2024542159A (ja) 2024-11-13
JP2024542159A5 true JP2024542159A5 (cg-RX-API-DMAC10.html) 2025-11-12

Family

ID=86242049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527078A Pending JP2024542159A (ja) 2021-11-04 2022-11-03 Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置

Country Status (9)

Country Link
US (1) US20240424099A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426350A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024542159A (cg-RX-API-DMAC10.html)
KR (1) KR20240107147A (cg-RX-API-DMAC10.html)
CN (1) CN118613271A (cg-RX-API-DMAC10.html)
AU (1) AU2022380926A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237016A1 (cg-RX-API-DMAC10.html)
IL (1) IL312555A (cg-RX-API-DMAC10.html)
WO (1) WO2023081317A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
CN118215683A (zh) * 2021-11-09 2024-06-18 悟境股份有限公司 记忆nk细胞和抗癌双特异性分子的组合癌症疗法
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650730A1 (en) * 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
US20130011376A1 (en) * 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
CA2983706C (en) * 2015-05-04 2024-01-02 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
PL3843757T3 (pl) * 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
EP4045539A4 (en) * 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof

Similar Documents

Publication Publication Date Title
AU2022204601B2 (en) Methods for enhancing efficacy of therapeutic immune cells
CA3019650C (en) Chimeric receptors and methods of use thereof
DK1648507T3 (en) PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
CN113383071A (zh) 用于t细胞工程化的组合物和方法
JP2023519099A5 (cg-RX-API-DMAC10.html)
JP2022512917A5 (cg-RX-API-DMAC10.html)
CA3118616A1 (en) Selection of improved tumor reactive t-cells
JP2025106512A (ja) 調節性ｔ細胞及びその使用
JP2024527559A5 (cg-RX-API-DMAC10.html)
AU2025203410A1 (en) Anti-TCR antibody molecules and uses thereof
KR20220134786A (ko) 면역치료용 조성물 및 방법
CA3134308A1 (en) Rituximab-resistant chimeric antigen receptors and uses thereof
JP2023519098A5 (cg-RX-API-DMAC10.html)
JP2024513958A5 (cg-RX-API-DMAC10.html)
US20250171731A1 (en) Methods of manufacturing allogeneic car t cells
US20230293685A1 (en) Selection of improved tumor reactive t-cells
CA3202483A1 (en) Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2021525068A (ja) Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
JP2021525067A (ja) Ｔ細胞悪性腫瘍の免疫療法のためのキメラ抗原受容体およびｃｄ２の遺伝子編集
IL324320A (en) Multi-receptor natural killer cells
KR20210099615A (ko) 감마 델타 t-세포 집단의 선택적 생체내 확장을 위한 방법 및 이의 조성물
KR20230007384A (ko) 치료 방법
US20240216430A1 (en) Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
RU2816370C2 (ru) Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения
JP2026502532A (ja) Ｔ細胞及びｎｋ細胞悪性腫瘍の免疫療法のためのｃｄ８発現及びキメラ抗原受容体の遮断